A randomised, double-blind, placebo-controlled study of the safety, pharmacokinetics and exploratory pharmacodynamics of AUT00206 for 28 days as adjunctive therapy in patients with recently diagnosed schizophrenia | C4C
The study will investigate the effects of a new pharmacological treatment for schizophrenia. We will be giving the new drug to patients diagnosed with schizophrenia (in addition to their current medication) for 28 days and we will use imaging methods (i.e. MRI, PET, EEG) and clinical measures to evaluate treatment response.